A&O Shearman guides joint lead managers on Novo Nordisk’s EUR6 billion deal

The following series of notes were issued:

• EUR1.4bn Floating Rate Notes due May 2027
• EUR1.45bn 2.375% Notes due May 27, 2028
• EUR1bn 2.875% Notes due August 27, 2030
• EUR900 million 3.125% Notes due May 27, 2033
• EUR1.25bn 3.625% Notes due May 27, 2037

Global financial markets partner Peter Crossan commented: “We are delighted to have supported the joint lead managers on this significant transaction for Novo Nordisk. The scale of this deal underscores the continued importance of the EMTN market for leading European corporates, and we are pleased to have played a role in its success.”

The A&O Shearman team was led by partner Peter Crossan alongside senior associate Michael Hossack, associate Charlotte Fuller and trainee Siobhan Ali.

Novo Nordisk is leading pharmaceutical company headquartered in Denmark. It specializes in the development of medicines and cures for diabetes and serious chronic illnesses such as obesity.

A&O Shearman has advised the dealers on the Novo Nordisk EUR20bn EMTN programme since its establishment in 2021 and the joint lead managers on the issuances thereunder including the EUR 4.65bn multi-series issuances in May 2024.